ORPHA:420611
Transient myeloproliferative syndrome
Also known as: Transient myeloproliferative disease · TMD · Transient abnormal myelopoiesis
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
1,111
Trials
4
Interventional, condition-specific
Researchers
1,278
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare hematologic disease characterized by clinical and morphological findings indistinguishable from those of acute myeloid leukemia, typically occurring in newborns with Down syndrome. Peripheral blood and bone marrow blasts display features suggestive of megakaryoblasts. In addition to trisomy 21, acquired GATA1 mutations are present in blast cells. Patients may be asymptomatic or present with thrombocytopenia, less commonly other cytopenias, leukocytosis, , jaundice, ascites, respiratory distress, bleeding, and pericardial or pleural effusions. Most patients undergo spontaneous remission within the first three months of life, although some may develop life-threatening hepatic, renal, or cardiac complications.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008040
- MeSH:C563551
- OMIM:159595
- UMLS:C1834582
- NCIT:C82339
Additional Mondo synonyms (11)
MST · TAM · Transient abnormal myelopoiesis associated with Down syndrome · leukemia, transient, of Down syndrome · transient abnormal myelopoiesis · transient leukaemia · transient leurkemia of Down syndrome · transient myeloproliferative disease · transient myeloproliferative disorder · transient myeloproliferative syndrome · transient myeloproliferative syndrome (disease)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,111 matched papers (537 in last 10 years) Source
- Phenotype characterisedPresent
3 HPO annotations (e.g. Transient myeloproliferative syndrome; Increased total leukocyte count; Down syndrome) Source
- Animal modelPresent
2 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
4 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
3
Associated phenotypes · MONDO:0008040
- Transient myeloproliferative syndrome
- Increased total leukocyte count
- Down syndrome
Animal models (Monarch / Alliance)
2
Model associations linked to this Mondo ID
- Gata1tm1Mym/Gata1tm1Mym Tg(Gata1*)#Mym/0 [background:] involves: 129P2/OlaHsd * C57BL/6 * DBA/2J·MGI:4450928·Mus musculus
- Gata1tm1Mym/Y Tg(Gata1*)#Mym/0 [background:] involves: 129P2/OlaHsd * C57BL/6 * DBA/2J·MGI:4450929·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0008040
- ASPARAGINASE·phase 3
- CYTARABINE·phase 3
- DAUNORUBICIN HYDROCHLORIDE·phase 3
- HYDROCORTISONE·phase 3
- METHOTREXATE·phase 3
- THIOGUANINE·phase 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,111
1,111 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,111 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
537 in the last 10 years · low confidence
Phrase hits: 1,111 · MeSH hits: 0
Who's working on it?
1,278
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ito E7 papers · 2026
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Papers in Europe PMC - 02Terui K7 papers · 2026
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Papers in Europe PMC - 03Chou ST6 papers · 2025
Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 04Hasegawa D6 papers · 2026
Department of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Papers in Europe PMC - 05Klusmann JH6 papers · 2026
Clinic for Pediatrics, University Hospital Frankfurt, Frankfurt, Germany.
Papers in Europe PMC - 06Roberts I6 papers · 2026
Department of Paediatrics and MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Papers in Europe PMC - 07Takasaki K6 papers · 2025
Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 08Toki T6 papers · 2026
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Papers in Europe PMC - 09Yokosuka T6 papers · 2026
Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Papers in Europe PMC - 10Bartram J5 papers · 2026
Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
4
interventional trials for this specific condition
4 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 11 September 2026
4 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 88.1th percentile).
low confidence · 88.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
4 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- isrctn·ISRCTN65011803·No longer recruiting·Effects of tamoxifen in patients with myeloproliferatIve disorders
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31682779·No longer recruiting·A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78830591·Stopped·AML-BFM 2012: clinical trial for the treatment of acute myeloid leukemia in children and adolescents
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41024033·No longer recruiting·Myeloid Leukaemia Down Syndrome 2006 for the treatment of myeloid leukaemia in children with Down syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54575263·No longer recruiting·Prevention of myeloid leukaemias in children with Down's syndrome and Transient Myeloproliferative Disorder
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Transient myeloproliferative syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Transient myeloproliferative syndrome" OR "Transient myeloproliferative disease" OR "Transient abnormal myelopoiesis" OR "Transient abnormal myelopoiesis associated with Down syndrome" OR "leukemia, transient, of Down syndrome" OR "leukemia, transient, of the Down syndrome" OR "transient leukaemia" OR "transient leurkemia of Down syndrome" OR "transient leurkemia of the Down syndrome" OR "transient myeloproliferative disorder" OR "transient myeloproliferative syndrome (disease)"
MeSH descriptor terms unioned into the query: Myeloproliferative Syndrome, Transient
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Transient myeloproliferative syndrome" OR "Transient myeloproliferative disease" OR "Transient abnormal myelopoiesis" OR "Transient abnormal myelopoiesis associated with Down syndrome" OR "leukemia, transient, of Down syndrome" OR "leukemia, transient, of the Down syndrome" OR "transient leukaemia" OR "transient leurkemia of Down syndrome" OR "transient leurkemia of the Down syndrome" OR "transient myeloproliferative disorder" OR "transient myeloproliferative syndrome (disease)" OR "Myeloproliferative Syndrome, Transient"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 4 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: TMD; MST; TAM
Confidence reasoning
- Preferred label is multi-word and distinctive
- 3 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1111) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T15:48:54.395Z
